KR20130065989A - Composition of healthy food - Google Patents
Composition of healthy food Download PDFInfo
- Publication number
- KR20130065989A KR20130065989A KR1020110132631A KR20110132631A KR20130065989A KR 20130065989 A KR20130065989 A KR 20130065989A KR 1020110132631 A KR1020110132631 A KR 1020110132631A KR 20110132631 A KR20110132631 A KR 20110132631A KR 20130065989 A KR20130065989 A KR 20130065989A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- extract
- food composition
- natural product
- natural
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 235000001497 healthy food Nutrition 0.000 title 1
- 239000000284 extract Substances 0.000 claims abstract description 46
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 42
- 230000036541 health Effects 0.000 claims abstract description 21
- 229930014626 natural product Natural products 0.000 claims abstract description 20
- 239000012141 concentrate Substances 0.000 claims abstract description 14
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229920001202 Inulin Polymers 0.000 claims abstract description 11
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 11
- 229940029339 inulin Drugs 0.000 claims abstract description 11
- ZMJBYMUCKBYSCP-UHFFFAOYSA-N Hydroxycitric acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000000654 additive Substances 0.000 claims abstract description 9
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 9
- 238000000605 extraction Methods 0.000 claims abstract description 8
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 8
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 8
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims abstract description 7
- 235000000832 Ayote Nutrition 0.000 claims abstract description 7
- 235000009854 Cucurbita moschata Nutrition 0.000 claims abstract description 7
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 claims abstract description 7
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 7
- 235000015136 pumpkin Nutrition 0.000 claims abstract description 7
- 229920001661 Chitosan Polymers 0.000 claims abstract description 6
- 229920001353 Dextrin Polymers 0.000 claims abstract description 6
- 239000004375 Dextrin Substances 0.000 claims abstract description 6
- 229920001100 Polydextrose Polymers 0.000 claims abstract description 6
- 244000088415 Raphanus sativus Species 0.000 claims abstract description 6
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 claims abstract description 6
- 235000019425 dextrin Nutrition 0.000 claims abstract description 6
- 239000001259 polydextrose Substances 0.000 claims abstract description 6
- 235000013856 polydextrose Nutrition 0.000 claims abstract description 6
- 229940035035 polydextrose Drugs 0.000 claims abstract description 6
- 240000004244 Cucurbita moschata Species 0.000 claims abstract 2
- 240000001949 Taraxacum officinale Species 0.000 claims abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 235000013376 functional food Nutrition 0.000 claims description 16
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims description 11
- 240000006891 Artemisia vulgaris Species 0.000 claims description 7
- 235000021579 juice concentrates Nutrition 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 244000061456 Solanum tuberosum Species 0.000 claims description 5
- 235000002595 Solanum tuberosum Nutrition 0.000 claims description 5
- 235000015277 pork Nutrition 0.000 claims description 5
- 230000000996 additive effect Effects 0.000 claims description 3
- 235000008216 herbs Nutrition 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 abstract description 22
- 235000020824 obesity Nutrition 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 20
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 14
- 210000004369 blood Anatomy 0.000 abstract description 8
- 239000008280 blood Substances 0.000 abstract description 8
- 235000012000 cholesterol Nutrition 0.000 abstract description 6
- 235000013305 food Nutrition 0.000 abstract description 5
- 230000002265 prevention Effects 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 230000001629 suppression Effects 0.000 abstract description 3
- 238000003809 water extraction Methods 0.000 abstract description 3
- 241000092668 Artemisia capillaris Species 0.000 abstract 1
- 235000008658 Artemisia capillaris Nutrition 0.000 abstract 1
- 244000065027 Artemisia princeps Species 0.000 abstract 1
- 235000017519 Artemisia princeps Nutrition 0.000 abstract 1
- 235000021559 Fruit Juice Concentrate Nutrition 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 240000008892 Helianthus tuberosus Species 0.000 abstract 1
- 235000003230 Helianthus tuberosus Nutrition 0.000 abstract 1
- 240000000691 Houttuynia cordata Species 0.000 abstract 1
- 235000013719 Houttuynia cordata Nutrition 0.000 abstract 1
- 241000534017 Saururus chinensis Species 0.000 abstract 1
- 235000008504 concentrate Nutrition 0.000 abstract 1
- 230000013872 defecation Effects 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 235000019197 fats Nutrition 0.000 description 17
- 235000005911 diet Nutrition 0.000 description 15
- 230000037213 diet Effects 0.000 description 15
- 241000593508 Garcinia Species 0.000 description 14
- 235000000885 Garcinia xanthochymus Nutrition 0.000 description 13
- 230000009471 action Effects 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 210000000577 adipose tissue Anatomy 0.000 description 6
- 230000003579 anti-obesity Effects 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 206010010774 Constipation Diseases 0.000 description 5
- 240000001980 Cucurbita pepo Species 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 241000245665 Taraxacum Species 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000001882 diuretic effect Effects 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 4
- 235000003097 Artemisia absinthium Nutrition 0.000 description 4
- 240000001851 Artemisia dracunculus Species 0.000 description 4
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 4
- 229920002527 Glycogen Polymers 0.000 description 4
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 108010028554 LDL Cholesterol Proteins 0.000 description 4
- 102000016267 Leptin Human genes 0.000 description 4
- 108010092277 Leptin Proteins 0.000 description 4
- 244000269722 Thea sinensis Species 0.000 description 4
- 239000001138 artemisia absinthium Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229940096919 glycogen Drugs 0.000 description 4
- 235000009200 high fat diet Nutrition 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 4
- 229940039781 leptin Drugs 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 238000001784 detoxification Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000005265 energy consumption Methods 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 description 2
- 241000208838 Asteraceae Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 235000014443 Pyrus communis Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229940108924 conjugated linoleic acid Drugs 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 235000009569 green tea Nutrition 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 244000298479 Cichorium intybus Species 0.000 description 1
- 235000007542 Cichorium intybus Nutrition 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 241000219130 Cucurbita pepo subsp. pepo Species 0.000 description 1
- 235000003954 Cucurbita pepo var melopepo Nutrition 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 210000000579 abdominal fat Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003627 anti-cholesterol Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 238000013542 behavioral therapy Methods 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 230000037180 bone health Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940111205 diastase Drugs 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000004136 fatty acid synthesis Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- -1 granular Substances 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229940089491 hydroxycitric acid Drugs 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000003880 negative regulation of appetite Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
- A23V2200/3324—Low fat - reduced fat content
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 건강기능성식품 조성물로서, 보다 상세하게는 천연물추출물을 주원료로 하는 체지방 및 체중 감량 효과를 갖는 비만 억제효능을 가지는 건강기능성식품 조성물에 관한 것이다.
The present invention relates to a health functional food composition, and more particularly, to a health functional food composition having an obesity inhibitory effect having a body fat and weight loss effect using a natural product extract as a main ingredient.
비만은 에너지 소모량에 비하여 에너지 섭취량이 많아서 체내에 과잉된 에너지가 지방으로 축적된 상태를 말하며, 2005년 국민건강영양조사에 의하면 우리나라 20세 이상 성인의 31.8%가 비만인 것으로 나타나 1995년도의 14.8%에 비하여 10년 동안 두 배 이상으로 증가되었다(Ministry of Health & Welfare. 2006. The third Korea National Health and Nutrition Examination Survey). 이러한 증가 추세에 따라 비만으로 인한 사회경제적 손실은 2001년도에 1조7천억원에서 매년 증가되고 있으며 정부의 국민건강 증진종합계획에서는 2010년까지 성인비만율을 30% 수준으로 유지하는 것을 주요 목표로 설정하고 있다(보건복지부. 2005. 국민건강증진종합계획. p61-64). 비만은 그 자체가 갖는 문제점뿐만 아니라, 심혈관계 질환이나 당뇨, 호흡기 질환, 골관절염 같은 질병을 유발할 수 있기 때문에 전 세계적으로 비만에 많은 관심이 모아지고 있으며(Antipatis V. J. et al., 2001,Obesity as a global problem. In International textbook of obesity. Per Bjorntorp, ed. John Wiley & Sons Ltd, Chichester, UK. p3-22), 세계보건기구(World Health Organization, WHO)에서는 비만을 세계적인 영양문제로 다루어 건강을 해치는 단순 위험인자가 아닌 치료해야 할 질병으로 인식하고 있다(World Health Organization. 1998. Obesity: Preventing and managing the global epidemic. Report of WHO Consultation on Obesity, Geneva). 비만은 에너지의 과다 섭취, 운동부족뿐 아니라 신경계 분비적 요인, 약물원인, 유전적 요인 등이 복합적으로 작용하므로 비만을 개선하기 위한 방법으로는 식사, 운동, 행동 요법이나 약물 치료 등이 쓰이고 있다.Obesity refers to a state in which excess energy is accumulated as fat due to high energy intake compared to energy consumption. According to the 2005 National Health and Nutrition Survey, 31.8% of adults over 20 years of age in Korea were obese. More than doubled over a decade (Ministry of Health & Welfare. 2006. The third Korea National Health and Nutrition Examination Survey). As such, the socio-economic loss due to obesity has increased from 1.7 trillion won in 2001 to 2001, and the government's comprehensive plan for promoting national health aims to maintain the adult obesity rate at 30% by 2010. (Ministry of Health and Welfare. 2005. Comprehensive National Health Promotion Plan. P61-64). Obesity is not only a problem of its own, but also can cause diseases such as cardiovascular disease, diabetes, respiratory disease, osteoarthritis, etc., so much attention has been paid to obesity worldwide (Antipatis VJ et al., 2001, Obesity as a global problem.In International textbook of obesity.Per Bjorntorp, ed.John Wiley & Sons Ltd, Chichester, UK.p3-22), the World Health Organization (WHO) treats obesity as a global nutrition problem It is recognized as a disease to be treated rather than as a simple risk factor (World Health Organization. 1998. Obesity: Preventing and managing the global epidemic. Report of WHO Consultation on Obesity, Geneva). Obesity is due to a combination of excessive energy consumption, lack of exercise, as well as neurological secretion factors, drug causes, genetic factors, etc. As a way to improve obesity, diet, exercise, behavioral therapy or drug treatment is used.
최근에는 부작용이 없는 식품 및, 천연물로부터 pancreatic lipase inhibitor의 개발을 위한 연구가 진행되고 있다(Yamamoto M. et al., 2000, Int. J. Obesity. 24:758-764).Recently, research has been conducted for the development of pancreatic lipase inhibitors from foods and natural products with no side effects (Yamamoto M. et al., 2000, Int. J. Obesity. 24: 758-764).
천연물을 활용한 항비만 소재 개발에 관한 결과를 살펴보면 작용기전 별로 식욕억제에 관여하는 물질로서 hydroxycitric acid(HCA), Olibra, 치커리, 이눌린 등의 식이섬유 등이 있으며, 지방의 소화 및 흡수를 저해하는 물질로서 키토산, flavonoids 등이 있다. 열 발생을 유도하여 지방 축적을 억제하는 물질로서 고추의 capsaisin, 녹차의 catechin, 레티노익산 등이 있고, 지질대사를 조절하는 L-carnitine, conjugated linoleic acid(CLA), 우유 칼슘과 관련 단백질 등이 보고되어 있다. 생약재로는 지실, 양하, 결명자, 녹차, 소나무 잎, 괴화, 천궁, 오수유 등이 체중조절에 효과가 있다는 결과가 보고되었다(Kim M. H., 2004, Korean J. Heath Psychol. 9:493-509, Reddy P. et al., 1998, Formulary 33:943-959, Burns A. A. et al., 2002, Eur. J.Clin. Nutr. 56:368-377, Delzenne N. M. et al., 2005, Br. J. Nutr. 1:157-161, Zacour A. C. et al, 1992, J. Nutr. Sci. Vitamilol. 38:609-613, Griffiths D. W. et al., 1986, Adv. Exp. Med. Biol. 1999:509-516).The results of the development of anti-obesity materials using natural products show that dietary fibers such as hydroxycitric acid (HCA), Olibra, chicory, and inulin are involved in appetite suppression according to the mechanism of action. Substances include chitosan and flavonoids. Examples of substances that induce heat generation and inhibit fat accumulation include capsaisin of red pepper, catechin of green tea, and retinoic acid, and L-carnitine, conjugated linoleic acid (CLA), which regulates lipid metabolism, and milk calcium and related proteins. It is. Herbal medicines such as fruit, yangha, deficiency, green tea, pine needles, hwahwa, cheongung, and filthy milk have been reported to be effective for weight control (Kim MH, 2004, Korean J. Heath Psychol. 9: 493-509, Reddy P. et al., 1998, Formulary 33: 943-959, Burns AA et al., 2002, Eur. J. Clin. Nutr. 56: 368-377, Delzenne NM et al., 2005, Br. J. Nutr 1: 157-161, Zacour AC et al, 1992, J. Nutr. Sci. Vitamilol. 38: 609-613, Griffiths DW et al., 1986, Adv.Exp. Med. Biol. 1999: 509-516) .
따라서 소비자들은 이와 같은 부작용이 적으며, 반대로 비만억제 및 예방 효과가 뛰어난 자연소재인 천연물에 더 많은 관심을 가지고 있으며, 이러한 요구에 부응하고자 안전하고 효능이 우수한 천연물의 약제의 개발이 요망되고 있는 실정이다.
Therefore, consumers are less interested in these side effects, and on the contrary, they are more interested in natural materials, which are natural materials with excellent anti-obesity and prevention effects, and in order to meet these demands, development of safe and effective natural medicines is desired. to be.
본 발명의 목적은 콜레스테롤 개선, 식후 혈당상승억제 및 배변활동을 원활하게 하는 천연물 추출물, 특히 변비와 숙변을 없애주고 해독작용 및 이뇨작용이 뛰어나며, 소화효소가 있어 소화를 촉진하는 천연물추출물 혼합물 또는 세포내 미토콘드리아에서 지방산을 합성해주는 시트레이트 리사스(citrate lysas)라는 효소의 작용을 방해하여 체지방이 만들어지는 과정을 차단하는 작용을 하는 가르시아캄보지아 추출물(HCA)을 주원료로 하는 천연물 혼합물을 포함하는 비만억제효능을 갖는 기능성 식품의 조성물을 제공하는 것이다.
It is an object of the present invention to improve cholesterol, suppress blood sugar levels after meals, and facilitate bowel movements, especially natural extracts or cells that eliminate constipation and stool, and detoxify and diuretic, and digestion enzymes to promote digestion Anti-obesity, including a natural product mixture based on Garcia cambogia extract (HCA), which acts to block the process of producing body fat by interfering with the action of an enzyme called citrate lysas, which synthesizes fatty acids in the mitochondria It is to provide a composition of a functional food having efficacy.
상기한 과제를 해결한 본 발명의 건강기능성식품 조성물은 천연물추출물 70~90중량%, 키토산 0.3~0.5중량%, 과일농축액 2.5~14.0중량%, 함수구연산 0.05~0.08중량% 및 기타첨가제 9.0~10.5중량%를 포함하는 것을 특징으로 한다. The health functional food composition of the present invention solved the above problems 70-90% by weight natural extract, 0.3-0.5% by weight chitosan, fruit concentrate 2.5-14.0% by weight, 0.05 ~ 0.08% by weight citric acid and other additives 9.0-10.5 It comprises a weight percent.
여기서, 상기 천연물추출물은 삼백초, 민들레, 돼지감자, 어성초, 약쑥, 인진쑥, 늙은호박, 무우를 혼합한 혼합물을 추출탱크에서 100~105℃온도조건하에 12~15시간 열수추출한 열수추출물인 것을 특징으로 한다. Here, the natural extract is characterized in that the hot water extract was extracted for 12 to 15 hours under 100 ~ 105 ℃ temperature conditions in the extraction tank, a mixture of three hundred seconds, dandelion, pork potato, eoseongcho, wormwood, jinjin mugwort, old pumpkin, radishes do.
여기서, 상기 천연물추출물은 가르시니아캄보지아 추출물, 마테추출물, 이눌린, 플럼과즙농축액, 난소화성덱스트린, 폴리덱스트로스, L-카르니틴을 혼합한 혼합물인 것을 특징으로 한다. Here, the natural extract is characterized in that the mixture of garcinia cambogia extract, mate extract, inulin, plum juice concentrate, indigestible dextrin, polydextrose, L-carnitine.
여기서, 상기 기타 첨가제는 자일로 올리고당, 올리고당 중 어느 하나 이상인 것을 특징으로 한다.
Here, the other additive is characterized in that any one or more of xylo oligosaccharides, oligosaccharides.
본 발명의 건강 기능성 식품 조성물은 천연물추출물이 가지고 있는 콜레스테롤 개선, 식후 혈당상승억제 및 배변활동을 원활하게 하는 천연물 추출물, 특히 변비와 숙변을 없애주고 해독작용 및 이뇨작용이 뛰어나며, 소화효소가 있어 소화를 촉진하는 천연물추출물 혼합물 또는 세포내 미토콘드리아에서 지방산을 합성해주는 시트레이트 리사스(citrate lysas)라는 효소의 작용을 방해하여 체지방이 만들어지는 과정을 차단하는 작용을 하는 가르시아캄보지아 추출물(HCA)을 주원료로 하는 천연물 혼합물을 포함함으로써 비만억제 및 예방의 효과를 높여주는 효과를 가짐과 동시에 체지방의 분해효능이 있어 다이어트용 식품으로서의 효능 또한 얻을 수 있다.The health functional food composition of the present invention is a natural product extract that has natural cholesterol extract, improves blood sugar suppression after meals, and facilitates bowel movements, in particular, eliminates constipation and stool, and has excellent detoxification and diuretic effects, digestive enzymes The main raw material is Garcia Cambogia Extract (HCA), which acts to block the process of making body fat by interfering with the action of natural extract extracts or citrate lysas, which synthesize fatty acids from intracellular mitochondria. By including a natural product mixture to increase the effect of inhibiting and preventing obesity and at the same time has the effect of decomposition of body fat can also obtain the efficacy as a diet food.
또한, 본 발명의 조성물은 과일농축액을 함유함으로써 천연물추출물의 특유의 거북한 맛을 상쇄시켜 식품으로 음용시 먹기 편한 맛을 느끼게 함으로써 음용자에게 거부감을 최소화할 수 있는 효과가 있다. In addition, the composition of the present invention has the effect of minimizing the objection to the drinker by containing the fruit concentrate to offset the peculiar taste of the natural product extract to feel easy to eat when drinking as food.
또한, 본 발명의 조성물은 고농축된 농축물 또는 상기 농출물을 건조시켜 미분쇄한 분말 형태로 수용성이 뛰어나 냉·온수에 즉시 용해되어 편리하게 섭취할 수 있으며, 고농축물로 차와 같은 형태로 적은 섭취량으로도 비만억제 및 예방 효과를 얻을 수 있으며, 액상, 과립상, 분말상 등 다양한 형태로 가공이 용이하여 식품보조제로도 활용이 가능하다.
In addition, the composition of the present invention is highly concentrated in the form of a concentrated powder or the dried product to be pulverized and excellent in water solubility is readily dissolved in cold and hot water and can be conveniently ingested, high concentration in the form of tea Ingestion can be used to prevent obesity and prevent effects, and can be easily processed into various forms such as liquid, granular, and powder.
이하, 본 발명을 바람직한 실험예를 들어 보다 상세히 설명하기로 한다. Hereinafter, the present invention will be described in more detail with reference to preferred experimental examples.
본 발명의 발명자는 콜레스테롤 개선, 식후 혈당상승억제 및 배변활동을 원활하게 하는 천연물 추출물, 특히 변비와 숙변을 없애주고 해독작용 및 이뇨작용이 뛰어나며, 소화효소가 있어 소화를 촉진하는 천연물추출물 혼합물 또는 세포내 미토콘드리아에서 지방산을 합성해주는 시트레이트 리사스(citrate lysas)라는 효소의 작용을 방해하여 체지방이 만들어지는 과정을 차단하는 작용을 하는 가르시아캄보지아 추출물(HCA)을 주원료로 하는 천연물 혼합물을 포함하는 비만억제효능을 갖는 기능성 식품의 조성물을 제공하고자 한다. The inventors of the present invention is a natural product extract, which improves cholesterol, suppresses post-prandial blood sugar elevation, and facilitates bowel movements, in particular, eliminates constipation and stool, and has excellent detoxification and diuretic effects. Anti-obesity, including a natural product mixture based on Garcia cambogia extract (HCA), which acts to block the process of producing body fat by interfering with the action of an enzyme called citrate lysas, which synthesizes fatty acids in the mitochondria It is intended to provide a composition of functional food having efficacy.
본 발명에 따라 제공되는 건강기능성식품 조성물은 체지방 및 체중 감량 효과를 갖는 천연물추출물을 주성분으로 포함하는 것으로, 천연물추출물 70~90중량%, 키토산 0.3~0.5중량%, 과일농축액 2.5~14.0중량%, 함수구연산 0.05~0.08중량% 및 기타첨가제 9.0~10.5중량%를 포함하여 이루어진다. The health functional food composition provided according to the present invention comprises natural extracts having a body fat and weight loss effect as main components, 70-90 wt% natural extract, 0.3-0.5 wt% chitosan, 2.5-14.0 wt% fruit concentrate, It comprises 0.05 to 0.08% by weight of hydrous citric acid and 9.0 to 10.5% by weight of other additives.
본 발명에 따르면, 상기 천연물추출물은 삼백초, 민들레, 돼지감자, 어성초, 약쑥, 인진쑥, 늙은호박, 무우를 혼합한 혼합물을 추출탱크에서 100~105℃온도조건하에 12~15시간 열수추출한 열수추출물이다. 바람직하게 상기 천연물의 열수추출물은 상기 각각의 천연물을 건조하여 분쇄된 분쇄물을 혼합한 혼합물을 추출한 것이며, 보다 바람직하게는 삼백초 5~6중량%, 민들레 11~12중량%, 돼지감자 14~15중량%, 어성초 7~8중량%, 약쑥 7~8중량%, 인진쑥 39~40중량%, 늙은호박 7~8중량%, 무우 7~8중량%를 포함하도록 혼합한 혼합물을 추출하는 것이다. According to the present invention, the natural product extract is a hot water extract of hot water extract for 12-15 hours under the temperature condition of 100 ~ 105 ℃ temperature in the extraction tank, a mixture of three hundred seconds, dandelion, pork potato, eoseongcho, wormwood, jinjin mugwort, old pumpkin, radish . Preferably the hot water extract of the natural product is to extract the mixture of the pulverized and crushed by drying the respective natural products, more preferably 5 to 6% by weight, dandelion 11 to 12% by weight, pork potato 14-15 7% to 8% by weight, 8-8% by weight, wormwood 7-8% by weight, 39-40% by weight of Jinjin mugwort, 7-8% by weight of old zucchini, 7-8% by weight of the beet is to extract a mixture.
상기 천연물추출물을 구성하는 인진쑥은 간기능을 보호하며 몸을 따뜻하게 하고 생리통, 생리불순 등 부인병에 효능이 있는 것을 잘 알려져 있으며, 약쑥, 민들레 및 어성초는 항염작용이 좋은 천연물로 다이어트 중에 나타날 수 있는 각종 염증과 항균작용에 도움을 줄 수 있는 소재이다. Injin mugwort constituting the natural extract is well known to protect the liver function and warm the body and is effective in gynecological diseases such as menstrual pain, menstrual disorders, etc., wormwood, dandelion and eoseongcho is a natural product with good anti-inflammatory action that can appear in the diet. It is a material that can help inflammation and antibacterial activity.
또한,삼백초는 변비와 숙변을 없애주고 해독 및 이뇨작용이 뛰어난 생약재로 알려져 있고, 무우는 디아스타제라는 소화 효소가 있어 위장을 튼튼하게 하며 소화를 촉진하는 역할을 한다. In addition, three hundred seconds to eliminate constipation and stool, and is known as a herbal medicine with excellent detoxification and diuretic effect, radish has a digestive enzyme called diastase to strengthen the stomach and promote digestion.
상기 호박은 각종 영양성분을 함유하고 있으며, 특히 이뇨 작용을 촉진시키는 성분이 많이 함유되어 있어 산후 부기 제거에 애용되어 왔다. 또한, 비타민 A인 카로틴이 풍부하게 함유되어 있고 위점막을 보호하는 기능이 있어 속이 아플 때도 효과가 좋은 것으로 알려져있다. 특히 생약도감에서는 호박을 보중익기(補中益氣)라고 기록되어 있다. Pumpkin contains a variety of nutrients, especially since it contains a lot of ingredients to promote the diuretic action has been used to remove postpartum swelling. It is also known to be rich in carotene, a vitamin A, and to protect the gastric mucosa. Especially in the herbal illustration, the pumpkin is written as Bojungikgi (補中益氣).
본 발명에 따르면, 상기 천연물 추출물은 가르시니아캄보지아 추출물, 마테추출물, 이눌린, 플럼과즙농축액, 난소화성덱스트린, 폴리덱스트로스, L-카르니틴을 혼합한 혼합물일 수 있으며, 상기 혼합물은 가르시니아캄보지아 추출물 1.5~2.0중량%, 마테추출물 3.0~3.5중량%, 이눌린 7~7.5중량%, 플럼(자두)과즙농축액 11.0 ~ 11.5중량%, 난소화성덱스트린 25.0~26.0중량%, 폴리덱스트로스 49~50중량%, L-카르니틴 1.5~2.0중량%를 포함한다. 이때, 상기 가르시니아캄보지아 추출물, 마테추출물, 플럼과즙농축액은 각각 적정비율의 원료를 추출탱크에 넣고 105℃에서 3시간 이상 열수추출하여 얻어지는 열수추출물을 사용한다. According to the present invention, the natural product extract may be a mixture of garcinia cambogia extract, mate extract, inulin, plum juice concentrate, indigestible dextrin, polydextrose, L-carnitine, and the mixture is 1.5-2.0 wt% of garcinia cambogia extract. , Mate extract 3.0-3.5%, inulin 7-7.5%, plum juice concentrate 11.0-11.5%, indigestible dextrin 25.0-26.0%, polydextrose 49-50%, L-carnitine 1.5-2.0 Contains by weight. At this time, the garcinia cambogia extract, mate extract, plum and juice concentrate, each using a hot water extract obtained by putting the raw material of the appropriate ratio in the extraction tank and hot water extraction at 105 ℃ for 3 hours or more.
바람직하게는 상기 열수추출물을 여과하고, 그 여과된 여액을 농축시켜된 농축물을 사용하는 것이 더욱 좋다. 상기 농축물은 점액질상일수 있으며, 건조된 상태에서 미분쇄한 분말일 수 있다. 상기 농축물이 점액질상일 경우, 그 점액질상의 고형분의 함량이 70~80%인 것이 바람직하며, 분말상일 경우에는 평균입도는 용해도를 높이기 위하여 10~30메쉬가 되도록 미분쇄하여 된 것을 사용하는 것이 바람직하다. Preferably, the hot water extract is filtered, and the filtered filtrate is more concentrated to use the concentrate. The concentrate may be in the form of mucus and may be a powder ground in a dry state. When the concentrate is a mucus, the solid content of the mucus is preferably 70 to 80%, and in the case of powder, the average particle size is preferably pulverized to 10 to 30 mesh to increase solubility. Do.
여기서, 상기 이눌린은 분자량 3,000~5,000의 국화과, 백합과 등의 근경이나 일부 구내연쇄구균의 세포 내에 교질 상태로 함유되어 있는 저장 다당류의 일종으로 주로 D-과당(약 98%)으로 구성된 β2→1결합의 과당중합체이고, 말단기는 α-글루코오스가 수크로오스결합하고 있는 하기 화학식 1의 구조를 가지고 있다. 이눌린은 백색의 둥근 결정으로 비교적 물에 잘 녹는다.Here, the inulin is a kind of storage polysaccharide contained in the state of the root of asteraceae such as asteraceae, liliaceae, etc., or some of the streptococci, with molecular weight of 3,000 to 5,000, and β2 → 1 mainly composed of D-fructose (about 98%). It is a bond hypersaccharide polymer, and the terminal group has the structure of the following general formula (1) in which α-glucose is sucrose-bonded. Inulin is a white round crystal that is relatively soluble in water.
[화학식 1][Formula 1]
상기 이눌린은 천연식이섬유로 장기능을 강화하여 배변이 원활해지고 변비와 설사를 예방해주며, 장내 유익한 영양제 역할로서 유익균의 성장과 활동성을 높여주며 유해균의 번식을 억제시켜 주는 역할을 한다. 또한, 칼슘의 흡수력을 증진시켜주어 뼈 건강에도 도움을 준다. 또한, 대장에서 이눌린이 대사되면 SCFA(저급지방산)을 생성하여 트리글리세라이드(Triglyceride)와 혈중콜레스테롤의 증가를 방지할 수 있다. The inulin is a natural dietary fiber to enhance bowel function to facilitate bowel movements and prevent constipation and diarrhea, and as a beneficial intestinal nutrients to increase the growth and activity of beneficial bacteria and to inhibit the growth of harmful bacteria. In addition, it improves the absorption of calcium, which helps bone health. Inulin is also metabolized in the large intestine to produce SCFA (lower fatty acids) to prevent the increase of triglycerides and blood cholesterol.
본 발명을 이루는 천연물추출물 혼합물을 구성하는 구성요소 중 하나인 가르시니아 캄보지아(Garcinia cambogia) 추출물(HCA)은 인도 원산 열대 과일인 가르시니아 캄보지아 껍질에서 추출한 것이다. 상기 가르시니아 캄보지아는 구띠페라(guttifera)과 가르시니아(Garcinia)종의 하나로 과피에는 HCA(Hydroxy Ctric Acid)가 10~30%(건조중량) 함유되어 있다. Garcinia cambogia extract (HCA), which is one of the components constituting the natural product extract mixture of the present invention, is extracted from the Garcinia cambogia bark, a tropical fruit native to India. The garcinia cambogia is one of the guttifera and garcinia species, and the skin contains 10-30% (dry weight) of HCA (Hydroxy Ctric Acid).
HCA는 오렌지나 다른 밀감류에 존재하는 구연산과 비슷한 물질로서 가르시니아 캄보지아라 칭한다. 가르시니아 캄보지아는 많은 식물에서 발견되는 구연산과는 달리 자연계에서 극히 드물게 발견된다. HCA is called Garcinia Cambogia, a substance similar to citric acid present in oranges and other citrus fruits. Garcinia cambogia is extremely rare in nature, unlike citric acid found in many plants.
HCA는 4가지의 이성체(수소원자와 산소원자가 네가지의 다른 배치를 취하고 있다.)가 발견되어 있으며, 가르시니아 캄보지아는 그중 하나로 다이어트 메카니즘에 작용하는 기능성분중의 하나이다.HCA is found in four isomers (hydrogen and oxygen atoms take four different batches), and Garcinia cambogia is one of the functional components in the diet mechanism.
HCA의 메카니즘은 체내와 탄수화물의 칼로리가 지질대사를 방해하고 글루코겐의 합성으로 전환시켜 에너지를 산출하는 것이다. 그로 인해 여분지방의 축적이 감소하여 다이어트 효과가 얻어진다. 즉, 뱃살 속의 지방 축적이 감소하여 다이어트 효과를 얻게 되는 것이다. The mechanism of HCA is that the calories in the body and carbohydrates interfere with lipid metabolism and convert to the synthesis of glucogen to produce energy. As a result, the accumulation of excess fat is reduced, resulting in a diet effect. In other words, the fat accumulation in the belly is reduced to obtain a diet effect.
상기 HCA의 다이어트 메카니즘에서의 작용을 설명하면 다음과 같다. The action of the HCA diet mechanism is described as follows.
1) 지방합성 억제1) inhibiting fat synthesis
비만은 체내에 있는 구연산이 ATP구연산 이아제라는 효소에 의해 분해되어 지방산이 됨에 따라 생긴다. 그러나, 가르시니아 캄보지아(HCA)와 ATP구연산리아제가 결합함으로써 구연산이 분해되지 않게 되어 지방합성이 이루어지지 않게 된다. Obesity occurs when citric acid in the body is broken down by enzymes called ATP citric acid enzymes to become fatty acids. However, by combining Garcinia cambogia (HCA) and ATP citric acid, citric acid is not decomposed and fat synthesis is not achieved.
이런 작용은 뱃살에 지방이 쌓이는 것을 방지하여 다이어트 효과를 내는 것이다. This action prevents the buildup of fat in the belly fat to produce a diet.
2) 에너지 생산의 증대2) increase in energy production
지방합성에 사용되지 않게 된 구연산은 그대로의 형태로 장기에 걸쳐 체내에 축적되어 글리코겐의 생성에 사용된다. 그 결과 글리코겐에서 에너지 생산이 장기간에 걸쳐 이루어져 토탈 에너지 생산량이 뚜렷하게 증대된다. Citric acid, which is no longer used for liposynthesis, is accumulated in the body in the form of organs and used to produce glycogen. The result is a prolonged energy production from glycogen, resulting in a marked increase in total energy production.
3) 식용억제3) Edible Inhibition
가르시니아 캄보지아(HCA)의 존재에 의해 글리코겐의 축적이 증가하면 당질의 과부족이 그대로 뇌의 시상하부에 전달되고 결과적으로 식욕이 억제된다. Increased glycogen accumulation due to the presence of Garcinia cambogia (HCA) is transmitted to the hypothalamus of the brain as it is, the lack of carbohydrates, and consequently suppresses appetite.
4) 지방의 분해 촉진4) Promote the breakdown of fat
가르시니아 캄보지아(HCA)에 의해 구연산이 분해되지 않기 때문에 그것에 의해 생산되는 마로닐 코아(COA)가 감소하여 농도가 저하된다. 마로닐 코아(COA)는 지방산의 합성과 분해의 양쪽 작용이 있어 농도가 저하되면 지방합성보다도 분해작용이 활발해지기 때문에 결과적으로 지방분해가 촉진된다. 따라서, 뱃살의 지방도 분해가 촉진되어 다이어트에 도움이 된다. Since citric acid is not decomposed by Garcinia cambogia (HCA), the amount of marlonyl core (COA) produced thereby decreases and the concentration falls. Maronyl core (COA) has both action of fatty acid synthesis and decomposition, and as the concentration is lowered, the decomposition activity is more active than fat synthesis, and consequently, lipolysis is promoted. Therefore, the fat of the belly fat is also promoted to help the diet.
5) 기초대사의 항진5) Enhancement of basic metabolism
위 1)~4)를 보면 가르시니아 캄보지아(HCA)의 존재하에 당질의 에너지화, 글루코겐의 축적, 지방의 에너지화가 어느 정도 동시에 진행되는 것을 알 수 있다. 이것은 생체에너지의 낭비이지만 체내에 축적된 지방을 소비하는 데는 효과적이다. 따라서, 에너지소비에 의한 기초대사의 항진을 짐작할 수 있다. In the above 1) ~ 4) it can be seen that in the presence of Garcinia cambogia (HCA), the energy of carbohydrate, the accumulation of glucogen, and the energy of fat proceed simultaneously. This is a waste of bioenergy, but it is effective in consuming fat that has accumulated in the body. Therefore, it is possible to estimate the enhancement of basic metabolism by energy consumption.
6) 체내 단백질의 보호6) protection of protein in the body
체내의 당질이 감소하면 그것을 채우기 위해 지방과 단백질을 원료로 당을 만들어내는 '신당성'이라고 불리는 작용이 일어난다. When the body's sugar decreases, a function called 'new sugar' occurs to make sugar from fat and protein to fill it.
가르시니아 캄보지아(HCA)가 존재하면 당질이 지방산으로 변화하지 않고 그대로 에너지가 글리코겐으로 변화하기 때문에 체내의 단백질은 분해되지 않는다. 그 결과로 단백질은 보호된다. The presence of garcinia cambogia (HCA) does not break down proteins in the body because the energy does not change to fatty acids but glycogen as it is. As a result, the protein is protected.
상기 다이어트 메커니즘에서 기능하는 가르시니아 캄보지아(HCA)의 안전성에 관해서는 다양한 임상시험의 결과 데이터로 일반 구연산과 동등하다는 결과는 이미 잘 알려져 있다. As for the safety of Garcinia cambogia (HCA) functioning in the diet mechanism, the results of various clinical trials are equivalent to general citric acid.
가르시니아 캄보지아(HCA)의 유일한 직접적 작용은 간세포에서의 지방합성을블록하는 것이며 그 이외에는 연쇄적으로 생기는 작용이다. The only direct action of Garcinia cambogia (HCA) is to block liposynthesis in hepatocytes, but in addition, it is a chain of action.
상기 가르시니아 캄보지아(HCA)는 이상에서 설명한 바와 같은 유익한 다이어트 효과를 가지고 있으나, 그 특유의 향과 맛으로 비유가 약한 사람에게는 거부감을 느낄 수 있는 하나의 단점이 있다. 그러므로, 이러한 거북한 맛을 상쇄시킬 수 있는 것이 필요하다. The Garcinia cambogia (HCA) has a beneficial diet effect as described above, but has one drawback that can feel a sense of rejection to those with a weak analogy with its unique aroma and taste. Therefore, it is necessary to be able to offset such awkward taste.
본 발명을 구성하는 상기 키토산은 체내에서 지방을 흡착하여 배출하는 작용을 한다. The chitosan constituting the present invention serves to adsorb and discharge fat from the body.
본 발명을 구성하는 상기 기타 첨가제는 자일로 올리고당, 올리고당 중 어느 하나 이상을 사용하는 것으로, 이들 중 어느 하나를 단독 또는 둘 이상을 사용한다. The other additive constituting the present invention is to use any one or more of xylo oligosaccharides, oligosaccharides, any one of them alone or two or more.
이상에서 설명되지 않은 과일농축액, 즉 사과농축액, 배 농축액 등은 통상적인 과일농축액 제조방법에 따라 준비된 것을 사용하였다.Fruit concentrates not described above, that is, apple concentrate, pear concentrate, and the like were prepared according to the conventional fruit concentrate production method.
이상에서 개시되는 본 발명의 건강기능성식품 조성물을 준비하고, 그 조성물을 이용하여 비만억제효능 및 효과를 검증하기 위한 실험을 실시하였다. 그 실험예는 하기에 기술된다. 단, 하기의 실험예로 본 발명을 한정하는 것은 아니다. The health functional food composition of the present invention disclosed above was prepared, and experiments were conducted to verify the anti-obesity efficacy and effect using the composition. The experimental example is described below. However, the present invention is not limited to the following experimental examples.
[실험예][Experimental Example]
<재료의 준비><Preparation of materials>
1. 동물 및 사료1. Animals and feed
본 실험을 위하여 사용된 C57BL/6 생쥐(♀, 20마리, 20∼24ｇ)는 (주)중앙실험동물에서 분양받아 조단백질 22.1%를 함유하는 고형사료(삼양사)와, 카제인과 고단백질(high protein) 26.0%, 비프탈로우(Beef tallow) 30.0%를 주원료로 함유하는 고지방 사료를 자유 식이하면서 물을 충분히 공급하였다. 동물 사육실의 조건은 conventional system으로 22±2 ℃, 1일 중 12시간은 200-300 Lux로 조명하고, 12시간은 모든 빛을 차단하였다. 고형사료투여군은 통상의 노말 다이어트군(the components of normal diet)이고, 고지방 사료는 고지방 다이어트군(the components of high-fat diet)이다. C57BL / 6 mice (♀, 20, 20-24 g) used for this experiment were fed from Central Experimental Animal Co., Ltd., solid feed containing 22.1% of crude protein (Samyang), casein and high protein (high protein). ) A high-fat diet containing 26.0% and 30.0% of beef tallow as a main ingredient was fed freely with sufficient water. The conditions of the animal breeding room were the conventional system, 22 ± 2 ℃, lighting for 12 hours in the day 200-300 Lux, 12 hours blocked all light. The solid feed group is the components of normal diet, and the high fat diet is the components of high-fat diet.
2. 본 발명의 건강기능성식품 조성물(이하, 'MhP1, MhP2'라 한다)2. Health functional food composition of the present invention (hereinafter referred to as 'MhP1, MhP2')
하기 표 1 및 2의 조성비로 건강기능성식품 조성물을 준비하였다. To prepare a health functional food composition in the composition ratio of Tables 1 and 2.
MhP1은 천연물 추출물로 삼백초 5.41중량%, 민들레 11.72중량%, 돼지감자 14.41중량%, 어성초 7.20량%, 약쑥 7.20중량%, 인진쑥 39.65중량%, 늙은호박 7.20중량%, 무 7.208중량%를 포함하도록 혼합한 혼합물을 추출탱크에 넣고 105℃에서 12시간 열수추출한 추출액을 여과한 다음 얻어지는 열수추출액을 준비하고, 나머지 첨가물을 순차적으로 투입하여 혼합한 다음, 99℃에서 5분간 멸균하여 준비하고, 그 준비된 혼합물을 100마이크론 필터로 여과하여 최종 조성물을 준비하였다. MhP1 is a natural extract that contains 5.41% by weight, 300% of dandelion, 11.72% by weight, 14.41% by weight of pork potatoes, 7.20% by weight of edible vinegar, 7.20% by weight of Mugwort, 39.65% by weight of Mugwort, 7.20% by weight of old pumpkin, 7.208% by weight of radish. The mixture was placed in an extraction tank and filtered after extracting hot water at 105 ° C. for 12 hours, and the resulting hot water extract was prepared. The remaining additives were added sequentially, mixed, and sterilized at 99 ° C. for 5 minutes to prepare the mixture. The final composition was prepared by filtration with a 100 micron filter.
MhP2는 천연물추출물로 가르시니아캄보지아 추출물 1.7중량%, 마테추출물 3.20중량%, 이눌린 7.02중량%, 플럼(자두)과즙농축액 11.28중량%, 난소화성덱스트린 25.53중량%, 폴리덱스트로스 49.57중량%, L-카르니틴 1.7중량%를 포함하도록 혼합한 혼합물을 사용하는 것을 제외하고는 MhP1과 동일한 방법으로 조성물을 준비하였다. 이때, 상기 가르시니아캄보지아 추출물과 마테추출물과 플럼과즙농축액은 각각 추출하기 위한 원료를 추출탱크에 넣고 105℃에서 3시간 열수추출한 다음 여과하여 준비된 것을 사용하였다.
MhP2 is a natural extract, Garcinia cambogia extract 1.7% by weight, Mate 20% by weight, Inulin 7.02%, Plum (plum) juice concentrate 11.28% by weight, Digestible dextrin 25.53%, Polydextrose 49.57%, L-carnitine 1.7% The composition was prepared in the same manner as MhP1 except that the mixture was mixed to contain%. At this time, the garcinia cambogia extract, mate extract and plum juice concentrate were used to prepare the raw materials for extraction in the extraction tank and then hot water extraction at 105 ℃ 3 hours and then filtered.
<실험><Experiment>
1. 사료의 식이와 검액의 투여1. Diet and Feeding Solution
사료의 식이는 준비된 사료를 증류수에 녹여 사용하였으며, 실험군의 구분은 일반 사료군(정상군), 고지방 사료군(대조군), Reductil 투여군(양성대조군), MhP1과 MhP2투여군(실험군)으로 나누어 10주 동안 자유식이 하였다. 동물의 몸무게가 8주 때에 33 g이 되었다. 이때부터, 시료의 경구 투여는 정상군과 대조군은 증류수를, 양성대조군인 Reductil 투여군은 10mg/kg 농도로, MhP1과 MhP2투여군은 각각 100 mg/kg 농도로 물에 타서 매일 경구 투여하였다.The diet of the feed was used by dissolving the prepared feed in distilled water, and the experimental groups were divided into the normal feed group (normal group), the high fat feed group (control group), the Reductil administration group (positive control group), and the MhP1 and MhP2 administration groups (experimental group) for 10 weeks. During the free meal. The animal weighed 33 g at 8 weeks. At this time, the oral administration of the sample was administered orally every day in the normal group and the control group in distilled water, 10 mg / kg concentration in the positive control group Reductil administration group, 100 mg / kg concentration in the MhP1 and MhP2 administration group, respectively.
2. 체중 측정2. Weight measurement
5주 동안 7일 간격으로 동물의 체중을 0.1 g 단위까지 측정하였다.Animals were weighed up to 0.1 g units at 7 day intervals for 5 weeks.
3. 혈액학적 분석3. Hematological analysis
체혈 및 혈청분리 측정, Cholesterol 함량 측정Measurement of body blood and serum separation, determination of Cholesterol content
-. 체혈 및 혈청분리는 Ether로 마취하여 심장에서 혈액을 채취한 후 3,000 rpm에서 15분간 원심분리 하여 혈청을 분리한 후 복강의 지방체 조직의 무게를 0.1 g 까지 측정하여 결과 값을 반영함.-. The body blood and serum separation was anesthetized with Ether, blood was collected from the heart, centrifuged at 3,000 rpm for 15 minutes to separate the serum, and the weight of the abdominal fat tissue measured to 0.1 g was reflected.
-. Cholesterol 함량 측정에서는 Total cholesterol의 함량은 enzymatic colorimetry method의 원리를 이용하여 생화학 자동분석기로 측정하였고, HDL, LDL-Cholesterol은 direct enzymatic assay를 이용하여 측정한 결과 값을 반영함.
-. The total cholesterol content was measured in the biochemical autoanalyzer using the principle of enzymatic colorimetry method, and the HDL and LDL-Cholesterol were measured by direct enzymatic assay.
<통계처리><Statistical processing>
실험 결과는 SPSS 11.0의 unpaired student's T-test를 사용하여 통계처리 하였으며 P<0.05, P<0.01 및 P<0.001 수준에서 유의성을 검정하였다.
The experimental results were statistically analyzed using the unpaired student's T-test of SPSS 11.0 and tested for significance at P <0.05, P <0.01 and P <0.001 levels.
<실험결과><Experimental Results>
1. 체중변화1. Weight change
시료 투여 시작 후 5주간의 체중 변화를 측정한 결과 아래 표 2와 같이 대조군에 비하여 MhP1과 MhP2투여를 통해 체중이 감소하는 것으로 나타났다.As a result of measuring the weight change of 5 weeks after the start of the sample administration, as shown in Table 2, the weight was decreased through the administration of MhP1 and MhP2 compared to the control group.
(10mg/kg)Positive control group
(10mg / kg)
(100mg/kg)MhP1
(100mg / kg)
(100mg/kg)MhP2
(100mg / kg)
2. 최종 체중증가량2. Final weight gain
시료 투여 시작 5주후 체중의 총 증가량을 계산한 결과 아래 표3과 같으며, 대조군에 비하여 MhP1과 MhP2 투여군에서 유의성 있는(p<0.001) 감소를 나타내었다.As a result of calculating the total increase in body weight 5 weeks after the start of the sample administration, it is shown in Table 3 below, and showed a significant (p <0.001) decrease in the MhP1 and MhP2 administration groups compared to the control group.
(10mg/kg)Positive control group
(10mg / kg)
(100mg/kg)MhP1
(100mg / kg)
(100mg/kg)MhP2
(100mg / kg)
3. 렙틴(Leptin) 함량의 변화3. Changes in Leptin Content
실험 종료 후 혈청에서 렙틴의 양을 측정하였으며, 그 결과 하기 표 4에서 보여지는 바와 같이 MhP1과 MhP2 투여군에서 유의성 있는(p<0.01) 감소를 나타내었다.After the experiment, the amount of leptin was measured in the serum, and as a result, as shown in Table 4, the MhP1 and MhP2 administration groups showed a significant decrease (p <0.01).
(10mg/kg)Positive control group
(10mg / kg)
(100mg/kg)MhP1
(100mg / kg)
(100mg/kg)MhP2
(100mg / kg)
(pg/㎖)Leptin
(pg / ml)
4. 총콜레스테롤, LDL, HDL-콜레스테롤의 변화4. Changes in Total Cholesterol, LDL, and HDL-Cholesterol
혈청에서 Total cholesterol, LDL, HDL-Cholesterol의 양을 측정하였으며, 그 결과 아래 표 5와 같이 대조군에 비하여 MhP1과 MhP2 투여군에서 유의성 있는(p<0.01) 감소를 나타내었다.The total cholesterol, LDL, and HDL-Cholesterol levels were measured in serum, and the results showed a significant (p <0.01) decrease in the MhP1 and MhP2 administration groups compared to the control group as shown in Table 5 below.
(10mg/kg)Positive control group
(10mg / kg)
(100mg/kg)MhP1
(100mg / kg)
(100mg/kg)MhP2
(100mg / kg)
(mg/dL)Gun-Chol.
(mg / dL)
(mg/dL)HDL-Chol.
(mg / dL)
(mg/dL)LDL-Chol.
(mg / dL)
<실험결과><Experimental Results>
본 발명에 따른 조성물의 고지방 사료의 식이로 비만이 유발된 생쥐를 이용하여 체중 변화, 혈액학적 변화를 관찰한 결과 다음과 같은 결론을 얻었다.Observations of weight change and hematological changes using the obesity-induced mice in the diet of the high fat diet of the composition according to the present invention resulted in the following conclusions.
1. 체중 변화 및 체중의 최종 증가량은 MhP1 100 ㎎/㎏, MhP2 100 ㎎/㎏투여군에서 유의성 있게 감소하였다.1. Body weight change and final increase in body weight were significantly decreased in MhP1 100 mg / kg and MhP2 100 mg / kg dose groups.
2. Leptin은 MhP1 100 ㎎/㎏, MhP2 100 ㎎/㎏ 투여군에서 유의성 있게 감소하였다.2. Leptin was significantly decreased in MhP1 100 mg / kg and MhP2 100 mg / kg.
3. Total cholesterol, HDL, LDL-cholesterol은 MhP1 100 ㎎/㎏, MhP2 100 ㎎/㎏투여군에서 유의성 있게 감소하였다.
3. Total cholesterol, HDL and LDL-cholesterol significantly decreased in MhP1 100 mg / kg and MhP2 100 mg / kg.
이상의 결과로 비추어 볼 때, 본 발명에 따른 조성물은 비만억제효과 뿐만 아니라 예방의 효과를 얻을 수 있는 것으로 파악되었다. 그와 동시에 다이어트의 효과도 얻을 수 있는 것을 확인하였다. In view of the above results, it was found that the composition according to the present invention can obtain not only the effect of obesity but also the effect of prevention. At the same time it was confirmed that the effect of the diet can be obtained.
Claims (4)
Health functional food composition comprising 70 to 90% by weight of natural extract, 0.3 to 0.5% by weight of chitosan, 2.5 to 14.0% by weight of fruit concentrate, 0.05 to 0.08% by weight of hydrous citric acid and 9.0 to 10.5% by weight of other additives .
상기 천연물추출물은 삼백초, 민들레, 돼지감자, 어성초, 약쑥, 인진쑥, 늙은호박, 무우를 혼합한 혼합물을 추출탱크에서 100~105℃온도조건하에 12~15시간 열수추출한 열수추출물인 것을 특징으로 하는 건강기능성식품 조성물.
The method of claim 1,
The natural product extract is a hot water extract, which is a hot water extract of hot water extract for 12-15 hours under the temperature condition of 100 ~ 105 ℃ temperature in the extraction tank mixed with three hundred seconds, dandelion, pork potato, eoseongcho, medicinal herbs, jinjin mugwort, old pumpkin, radishes Functional food composition.
상기 천연물추출물은 가르시니아캄보지아 추출물, 마테추출물, 이눌린, 플럼과즙농축액, 난소화성덱스트린, 폴리덱스트로스, L-카르니틴을 혼합한 혼합물인 것을 특징으로 하는 건강기능성식품 조성물.
The method of claim 1,
The natural extract is a health functional food composition, characterized in that the mixture of garcinia cambogia extract, mate extract, inulin, plum juice concentrate, indigestible dextrin, polydextrose, L-carnitine.
상기 기타 첨가제는 자일로 올리고당, 올리고당 중 어느 하나 이상인 것을 특징으로 하는 건강기능성식품 조성물.
The method of claim 1,
The other additive is a health functional food composition, characterized in that any one or more of xylo oligosaccharides, oligosaccharides.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020110132631A KR20130065989A (en) | 2011-12-12 | 2011-12-12 | Composition of healthy food |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020110132631A KR20130065989A (en) | 2011-12-12 | 2011-12-12 | Composition of healthy food |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20130065989A true KR20130065989A (en) | 2013-06-20 |
Family
ID=48862376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020110132631A KR20130065989A (en) | 2011-12-12 | 2011-12-12 | Composition of healthy food |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20130065989A (en) |
-
2011
- 2011-12-12 KR KR1020110132631A patent/KR20130065989A/en not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100645385B1 (en) | Composition for anti-obesity | |
| CN107319525A (en) | One kind fat-reducing fat reducing tailored version clinical nutrition formula and preparation method thereof | |
| KR101738912B1 (en) | Composition For Anti-obesity And Diet | |
| KR20120003693A (en) | Anti-obesity composition comprising red grape extracts, green tea extracts, soybean extracts, and l-carnitine | |
| KR101614574B1 (en) | Composition of Diabetes-Improving Effective Constituents by Fermentation Products of the Trifoliate Orange | |
| KR101447231B1 (en) | A manufacturing method of overhang solution pellet and overhang solution pellet munufactured by the same | |
| KR101695848B1 (en) | A composition comprising ginsenoside f2 for preventing or treating non-alcoholic liver disease | |
| KR101045279B1 (en) | Composition of functional food with weight loss effect | |
| KR101859166B1 (en) | A composition for removing hangover comprising an herb extract including ginseng | |
| KR20200016608A (en) | The health food composition for regulating weight | |
| KR20160141027A (en) | Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder | |
| EP1583547B1 (en) | Anti-obesity ingredients from medicinal plants and their composition | |
| JP2006104182A (en) | Composition for reducing body fat | |
| KR102470155B1 (en) | Oral composition for reducing body weight or body fat comprising Artemisia dracunculus and Taraxacum officinale | |
| JP2002173435A (en) | Antiobestic drug and medication method for the same | |
| Jung et al. | L-ascorbic acid addition to chitosan reduces body weight in overweight women | |
| JP2001269135A (en) | Nutritional composition capable of promoting body protein accumulation efficiency | |
| CN109805235B (en) | Wheat-flavor composite polypeptide solid beverage for assisting in reducing hypertension, hyperglycemia and hyperlipidemia, and preparation method and application thereof | |
| KR101373493B1 (en) | Composition comprising Hizikia fusiformis for preventing and treating obesity or hyperlipidemia and atherosclerotic-vascular diseases | |
| KR20150044014A (en) | Extract for anti-obesity inhibiting digestion and absorption and method for producing the same | |
| EP2155220B1 (en) | Compositions comprising Herba Ephedrae and Thallus Laminariae seu Eckloniae for use in supressing obesity | |
| KR20130065989A (en) | Composition of healthy food | |
| KR101293032B1 (en) | Pharmaceutical composition for treating or preventing obesity comprising sea tangle and sodium butyrate as effective component | |
| JP2020137496A (en) | Composition containing mulberry leaf processed product | |
| KR101459665B1 (en) | Food composition with Agarum cribrosum against constipation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |